Latest research findings, TGA updates, and community insights on GLP-1 peptides and research compounds in Australia.
New maintenance data from Viking's VK2735-102 study shows up to 97% of weight loss held after switching to every-other-week dosing. What it means for the maintenance question.
Griffith University-led research on nearly 15,000 people with bipolar disorder found semaglutide was associated with a 21% lower risk of psychiatric hospitalisation.
Tirzepatide is now the first dual GIP/GLP-1 agonist with an FDA cardiovascular indication, after a 13,000-participant head-to-head trial against Trulicity.
The TGA tested a vial sold as retatrutide after a user tore their oesophagus vomiting. It held semaglutide at eight times standard strength.
UC Berkeley researchers gave 20-month-old mice semaglutide and they lived nearly 100 days longer. The calorie restriction mimetic claim, examined.
Semaglutide has been on Wada's monitoring list since 2024. For 2027 the prohibited list stays unchanged while studies continue. What it means.
UK health records show semaglutide users had fewer asthma attacks and COPD flare-ups. What the ERS 2026 data means for lung health research.
Novo's STEP Young trial moved 40.4% of children aged 6 to 11 below the obesity threshold. Plus new US data on a 310-fold rise in paediatric GLP-1 prescribing.
An npj analysis of 63,215 patients found higher semaglutide doses tied to fewer neuropsychiatric events. A counter-narrative to the suicidality scare.
Novo Nordisk's oral semaglutide pill hit German pharmacies on 1 September - the first EU country launch. What it means for the GLP-1 market and Australia.
Lab testing of black-market retatrutide found over-strength vials, underdosed vials, and one with no active ingredient at all. Here is what the data shows.
The FDA's compounding advisory committee recommended six peptides for the 503A Bulks List, against staff advice. Here is what the vote did and did not decide.
New Science Advances research on TOFA shows a small molecule that burns fat and fights fatty liver in mice without muscle loss, and it stacks with GLP-1s.
New data shows black market 'reta' users lose far less weight than trial participants, as Victorian health authorities investigate counterfeit batches linked to liver failure.
A 53,000-person BMJ analysis links tirzepatide to fewer heart attacks, strokes, deaths and severe infections than an older diabetes drug. Here's the detail.
The TGA and NSW Police executed search warrants and seized more than $120,000 of unapproved peptides including retatrutide and the Wolverine Stack.
A new oral nonpeptide GLP-1 agonist from China delivered up to 9.7% weight loss in a 16-week Phase 2 trial. Here's what the data shows.
While regulators debate loosening peptide access, enforcement is catching up. A vendor got 70 months and a compounder recalled endotoxin-contaminated vials.
Eli Lilly filed six lawsuits against sellers of knockoff retatrutide and called on platforms and regulators to help close the black market.
From 'Ozempic butt' to the tirzepatide vs semaglutide debate, muscle loss is one of the loudest GLP-1 topics. Here is what the evidence actually shows.
Neurocrine Biosciences has begun a Phase 1 trial of NBIP-1968, a GLP-1/GIP/glucagon triple agonist for obesity. Here is why the class keeps growing.
Eli Lilly has announced an expanded access program for retatrutide ahead of FDA approval. Here's what the triple agonist access pathway looks like.
ABC News journalists successfully ordered unapproved peptides through social media channels. The investigation shows the gap between regulation and reality.
New research from UNSW Sydney reveals half a million Australians regularly use GLP-1 medicines, with private prescriptions driving the surge.
Lilly's triple agonist retatrutide delivered 30.3% average weight loss in TRIUMPH-1, and the company has now filed for FDA approval.
TGA crackdowns, hospitalisations, and an underworld of unapproved peptides - the gap between legal frameworks and real-world use keeps growing.
Stanford researchers used AI to discover a naturally occurring molecule that activates GLP-1 pathways without the gastrointestinal side effects of current drugs.
The FDA advisory committee is meeting July 23-24 to vote on whether BPC-157, TB-500, and five other peptides should be available for compounding. Here's what to expect.
Samsung Biologics is acquiring Swiss peptide manufacturer PolyPeptide for $1.8B. What this means for the peptide supply chain and research access.
A large BMJ Open study found GLP-1 receptor agonists reduced alcohol-related hospital admissions by 26%. What the research says about GLP-1s and addiction.
A new Nature Communications study found semaglutide slowed epigenetic aging markers by 9%. Here's what that means for the research community.
A new BMJ network meta-analysis found most GLP-1 drugs cause weight loss but don't meaningfully improve quality of life or heart health. The nuance matters.
Vertex's $10B Crinetics acquisition signals massive commercial confidence in oral peptide delivery. What it means for the research peptide space.
Novo Nordisk's oral semaglutide pill hit UK pharmacy shelves on July 6. Boots is selling it from £79. Australia is still waiting.
Washington Post, CBS News and a crypto investigation all found unapproved retatrutide being sold openly. The underground market is worth $100 million.
Novo signed a deal with Vivani Medical to evaluate a tiny semaglutide implant that could last months. The delivery method wars are here.
FDA career scientists are pushing back against expanded peptide access ahead of a crucial July advisory committee meeting. Here's what's at stake for BPC-157, TB-500, and more.
A new Hone Health survey found 50% of peptide users think their compounds are FDA-approved when they're not. Here's what the data actually shows.
Eli Lilly's orforglipron pill, branded as Foundayo, became the first oral GLP-1 approved by the FDA. Now it's part of Medicare's new weight-loss drug program.
Eli Lilly gave one patient special FDA access to retatrutide before approval. The story has sparked a massive debate about access, equity, and the expanded access program.
Victoria's Chief Health Officer has issued a health alert after six cases of acute liver toxicity linked to counterfeit retatrutide products.
Corxel's CX11 oral obesity pill hit 11.5% weight loss in Phase 2 trials and is heading to Phase 3. The race for a needle-free GLP-1 is heating up.
A JAMA Psychiatry study found 32% of people with eating disorders have used GLP-1 drugs, with 10% reporting misuse. Here's what the data shows.
Harm-reduction services in Western Australia say people accessing needles for peptide use has doubled in three years, with demographics shifting fast.
Two hacking groups targeted Novo Nordisk and attempted multi-million dollar ransoms. Here is what the research community should know.
The FDA has issued warning letters to telehealth companies for false and misleading claims in their marketing of compounded GLP-1 weight loss drugs.
The US Medicare system will offer GLP-1 drugs for $50 from July 1. A temporary program that may not stay temporary.
Pfizer spent big to enter the obesity race. New data from ADA 2026 shows whether that bet is paying off.
The ADA 2026 conference showed Lilly's retatrutide setting new standards while Pfizer and Roche face differentiation challenges.
AstraZeneca is pushing its oral GLP-1 pill elecoglipron into Phase 3 trials. Here's what the Phase 2 data showed.
The American Diabetes Association meeting delivered major data on retatrutide, CagriSema, and the next wave of obesity treatments. Here's what matters.
Australian media outlets are increasingly covering the peptide and GLP-1 phenomenon. Here's what the recent reporting tells us.
The TGA has updated its compounding framework. Here's what researchers need to know about the current regulatory landscape.
Insurance companies are routing patients through telehealth platforms to manage obesity drug costs. Not everyone thinks that's a good idea.
New studies suggest GLP-1 drugs may reduce cancer risk in 6 out of 7 cancers studied. Here's what the research actually says.
Eli Lilly's triple agonist retatrutide continues to advance through Phase 3 trials. Here's what the latest data reveals.
Injectable peptides dominate the GLP-1 landscape, but oral alternatives are advancing. Here's where the research stands.
Boehringer Ingelheim's dual agonist survodutide is generating interest for its effects on liver fat metabolism.
Boehringer Ingelheim's survodutide faces scrutiny after new Phase 3 data. Here's what the latest results suggest.
Australian interest in peptide research is surging. Here's how the community is evolving and what's driving the growth.
Novo Nordisk's combination of semaglutide and cagrilintide represents a new approach to metabolic research. Here's what we know.
A beginner-friendly guide to understanding peptide research, Australian regulations, and building research literacy as a community member.
Current Ozempic supply situation in Australia, TGA shortage listings, and the research landscape for alternative GLP-1 compounds.
Retatrutide (LY3437943) activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trial data and what it means for metabolic research.
Understanding the TGA framework is essential for anyone interested in peptide research in Australia. Here's a practical guide.
GLP-1 receptor agonists have shown significant effects on weight management in clinical trials. Here's how the science works.
Understanding research methodology is essential for evaluating peptide studies. Here's a practical guide for the research community.